Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC
Status:
Unknown status
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
This study is conducted to explore the safety and efficacy of anlotinib, a tyrosine kinase
inhibitors of Vascular Endothelial Growth Factor Receptor 2（VEGFR）、FGFR（Fibroblast Growth
Factor Receptor）, Platelet-derived growth factor Receptor（PDGFR） and c-kit, vs docetaxel in
advanced Non-squamous Non-small cell lung cancer harbouring wild-type epidermal growth factor
receptor (EGFR) .